T he surgical management of glaucoma offers the potential to lower intraocular pressure (IOP) independent of patients' compliance with their medication regimen. Procedures such as trabeculectomy and tube shunt placement often yield large magnitudes of IOP reduction, but may be associated with short-and long-term complications. Microinvasive glaucoma surgery (MIGS) offers an alternative surgical approach that is inherently less invasive; however, most devices that fit in this category are associated with a lesser degree of IOP-lowering efficacy compared with traditional glaucoma surgeries. A newer MIGS device, a gel stent that facilitates drainage to the subconjunctival space, appears to offer similar IOP reduction to trabeculectomy, but with much less tissue manipulation; better predictability; and less sight-threatening complications, thus making it a potentially safer and more predictable surgical option in appropriate patients. The following proposed protocol, based on evidence-based practices and augmented where necessary by the opinions of experienced surgeons, provides guidance for the pre-, intra-, and postoperative management of patients receiving a gel stent implant. The goal of this protocol is to provide a framework for better patient selection and preparation, surgical pearls, and how best to assess and manage patients in the postoperative period.
Trabeculectomy and tube shunt surgeries have an important role in glaucoma management, offering the ability to achieve intraocular pressure (IOP) lowering independent of patients' compliance in appropriate candidates. Both trabeculectomy and tube shunt drainage devices, performed using an ab externo approach, achieve lowering of IOP via drainage of aqueous from the anterior chamber (AC) to the subconjunctival space. 1 However, each of these procedures is associated with a lengthy and variable recuperation and prolonged time to visual recovery. In some instances, there is associated loss of best-corrected visual acuity (BCVA) and significant risk of short-and long-term complications, including hypotony, choroidal effusion, cataract, and flat or shallow anterior chamber, as well as valve-related complications, such as tube blockage, erosion, and endothelial cell loss. [1] [2] [3] [4] An alternative option, in the form of microinvasive glaucoma surgery (MIGS) devices, is associated with clinically relevant IOP lowering with an improved safety profile and recovery compared with trabeculectomy and tube shunts. 5 There are several devices fitting the definition of MIGS; they can be categorized by their intended mechanism of action. 6 For instance, they may improve outflow by targeting the trabecular meshwork (TM), Schlemm canal, or the supraciliary space.
A MIGS drainage device implanted via an ab interno approach that facilitates drainage of aqueous from the AC to the subconjunctival space (Xen ® 45; Allergan, Irvine, CA) has recently been approved in the US for use in the surgical management of glaucoma. This device, which can be used as a standalone procedure, offers the potential to achieve IOP lowering that is comparable to trabeculectomy, but with less tissue manipulation. 7, 8 The device, which is implanted using a handheld disposable injector, is Gel Stent Implantation-Recommendations constructed from porcine-derived gelatin that is formed into a tube and cross-linked with glutaraldehyde, thus allowing it to expand and remain flexible when hydrated. The expansion of the tube's outer diameter when in contact with fluid also aids in retention of the gel stent in its intended location after surgical implantation, which helps minimize many of the issues associated with synthetic materials, such as migration, erosion, and corneal endothelial damage. 9 The gel stent was designed using principles established by the Hagen-Poiseuille equation, whereby outflow resistance to the fluid increases linearly in proportion to the length of the tube, and decreases to the fourth power of the diameter of the tube lumen. In sum, a longer and thinner tube provides greater resistance than a shorter and wider tube. 10 In the US, the gel stent is indicated for the management of refractory 
Expert principles for implantation
The following recommendations were developed based on the clinical experience of the authors, all of whom were involved in the development of the gel stent and also have considerable surgical experience with the device. The objective of the protocol is to present evidence-based practices, augmented with the opinion of the authors, as guidance for the management of gel stent patients during the pre-, intra-, and postoperative periods. (Note: for the purposes of this paper, the terms "gel implant" and "gel stent" will be used interchangeably.) A summary of this protocol is available in Figure 1 . Fundamentally, the guidance is informed by three main principles: to minimize bleeding during implantation, lower conjunctival resistance, and control inflammation.
Bleeding during implantation may impair visibility of crucial steps of the implant procedure and/or incite the release of inflammatory cytokines 12 that facilitate fibrosis. 13, 14 It has been reported that lowering conjunctival resistance to outflow increases the likelihood of achieving sustained IOP lowering. 13 Finally, control of inflammation mediates an important cause of fibrosis and bleb failure in subconjunctival filtering procedures.
13,14

Preoperative considerations
Although not explicitly stated as part of the "preparation" phase noted in Figure 1 , proper patient selection and preparation are implied critical elements for successful gel stent implantation. Also falling under the category of "preparation" is education and counseling of patients so as to establish reasonable postoperative expectations.
Implantation of the gel stent has been shown to correspond to an early postoperative pressure gradient between 6 and 8 mmHg following an uncomplicated implantation under normal physiologic conditions and without conjunctival resistance to the outflow. 10 The pressure gradient is a result of the resistance of the implant (which stays constant) and the resistance to outflow under the conjunctiva (which changes as the bleb evolves over time). Thus, as general guidance, patients requiring a target pressure in the low to mid-teens would seem to be suitable candidates for this type of implant. Implantation of the gel stent represents a minimally invasive and more controlled and predictable means of achieving a pressure within this range while also reducing (and in many cases eliminating) the need for postoperative IOP-lowering medication use. As a result, postoperative recovery is often faster compared with trabeculectomy and tube surgeries. 7, 15 Detecting and treating comorbid conditions, particularly ocular surface disease/dry eye and blepharitis, can help reduce important causes of inflammation. 16 In the presence of conjunctival injection, stopping IOP-lowering medications (and, if necessary, replacing them with oral acetazolamide) a few weeks prior to surgery may be considered along with use of topical steroids and preservative-free lubricants to reduce ocular Review Glaucoma surface inflammation ( Figure 2) . 17 Operating on a quiet eye with a healthy conjunctiva, and preferably one that has not undergone previous surgery involving conjunctiva in the target quadrant, establishes conditions that increase the likelihood of successful implantation. Pseudophakic eyes, or those planned to undergo concomitant cataract surgery, may comprise a more straightforward operating environment early in the surgeon's learning curve, allowing easier access (i.e. a deep AC) and accurate implant placement at the angle, with less potential to induce inflammatory responses. Also, the concomitant need for cataract surgery may represent an opportunity to simultaneously perform a procedure that will help the patient achieve control of IOP along with visual rehabilitation.
Perioperative considerations
The "preparation" phase of gel stent implantation continues to the perioperative period with choice of anesthesia, which will likely depend on several factors; however, pain avoidance will decrease the potential for release of proinflammatory cytokines, 18 and attendant scar tissue formation and bleb failure.
14 Surgeons may opt to use a regional block, especially in early cases, to minimize the potential for patient or ocular movements that may lead to iatrogenic trauma. Generally speaking, the anesthesia requirement for implantation of the gel stent is no different to that of other ocular surgeries, including trabeculectomy. Many surgeons find the use of topical anesthesia alone to be more than sufficient for surgical comfort.
Hydroexpansion and adjunctive use of antifibrotic agents during gel stent surgery
The objective of hydroexpansion is to separate conjunctival and Tenon tissue layers surrounding and adjacent to the desired implant location in the subconjunctival space, 13 thus preparing the space for the implant and supporting formation of the bleb (see step 2, Figure 1 ). Performing this step In the context of trabeculectomy, use of lower doses of MMC is associated with adequate suppression of fibrosis, with a better safety profile compared with higher doses. 22 As such, the authors' techniques for using MMC have evolved over the course of their experience implanting the gel stent, moving over time to lower doses than are typically used in trabeculectomy surgeries. In the authors' opinion, injecting a large volume of MMC, over 0.1 mL, increases the risk of pooling in the limbus, anterior bleb formation, and conjunctival avascularity. Based on the above-mentioned literature, This placement will allow the hydroexpansion fluid to migrate without pooling at the limbus. To avoid bleeding, blood vessels should be avoided as the hydroexpansion needle is introduced into and through the subconjunctival space. Bleeding may compromise visibility or result in bleb malfunction postoperatively. 4 
Surgical technique
Achieving a perfectly positioned implant must engender consideration for optimal positioning with respect to quadrant, which, in turn, has a bearing on where the bleb will form. Because a nasally forming bleb may result in bleb dysesthesia, cosmetic issues, and/or bleb-related complications, 24 ideal gel stent positioning would appear to be between 12:00 and 1:30 o'clock OD and between 10:30 to 12:00 o'clock OS. While positioning as close to 12:00 o'clock as possible is preferable, this level of precision may be difficult to achieve, especially during the learning curve. Accurate positioning may also be difficult in patients with either a deep eye or prominent cheekbone, in which case a more temporal incision with a more tangential pass will permit easier access for the injector needle.
During all phases of implanting the gel stent, it is critical to avoid iatrogenic trauma to reduce the risk of bleeding events. Conjunctival bleeding events, if they occur, can typically be addressed using external tamponade with a blunt instrument. Confirming final placement and outflow If present, any and all blood should be thoroughly removed from the AC as this is a risk factor for implant blockage and release of inflammatory cytokines 12 that may increase the likelihood of postoperative bleb failure.
13,14
The final part of the "priming" phase is to thoroughly hydrate all incisions to ensure that pressure and a formed AC are maintained.
Considerations for unsatisfactory implant placements
Following implantation, if the gel stent is deemed immobile or excessively curled or twisted, the surgeon should consider liberating the implant intraoperatively (the authors refer to this as step as "primary needling").
The technique for achieving this, while analogous to the "needling" procedure described in the literature 10 used to mechanically break down scar tissue following failed glaucoma filtration procedures, is much less invasive. One approach to performing this maneuver is use a gentle "slide and swipe" technique by inserting a 30-gauge needle below the implant and then to moving it in the direction of the fornix, repeating this with insertion of the needle above the implant when necessary (see Primary Needling Video, available at www.touchOPHTHALMOLOGY.com).
Primary needling is the authors' preferred first option for an immobile implant when the implant is excessively curled (i.e. "pig tailed"), which is unlikely to provide for adequate posterior aqueous flow postoperatively, or when the implant is placed such that interstitial resistance could limit aqueous flow. If the implant is free and mobile at its distal end, primary needling may not be necessary even if the implant is slightly curved.
Nevertheless, the surgeon may still wish to correct the implant's positioning using a blunt instrument, applying gentle posterior force and directing it away from the limbus. If unsuccessful with this step, manipulation of the conjunctiva around the area of the implant may free the obstruction.
As a last resort, primary needling of the surrounding tissue may liberate the implant with the caveat that this step may be associated with increased risk of bleeding.
As noted earlier, a 1-2-3 positioning is most likely to achieve the desired location of outflow postoperatively. If that is not achieved, the implant should be repositioned before the surgery is concluded. The authors' opinions for adjusting suboptimal implant length position is as follows.
• Not connected or too short in the AC: in scenarios where the connection into the AC is deemed too short or not visible (i.e. implant is buried into angle tissue), a reasonable step is to use forceps at the scleral exit site, pushing the implant back slightly into the AC.
• Not connected or too short in subconjunctival space: if the implant is too short under the conjunctiva or not visible, the most straightforward solution is usually to remove the implant from the AC through the main incision with microforceps (i.e. vitrectomy forceps, anterior chamber microinstruments, etc.), reload the implant in the injector, and attempt a second implantation maneuver. This approach is also recommended when the implant is placed too nasally or if the scleral channel is too short.
• Slightly short in subconjunctival space: in scenarios where small length adjustments are necessary under the conjunctiva, it is reasonable to use forceps to pull the implant further into the subconjunctival space. It is important to understand that because of the conjunctival anatomy and insertion at the limbal area, a tissue slack will be necessary before grabbing, holding, and pulling the implant out into the subconjunctival space (see Repositioning Video, available at www.touchOPHTHALMOLOGY.com).
Postoperative considerations
Similar to trabeculectomy, the requirements for the postoperative period following gel stent implantation are based on IOP measurements taken during follow-up examination (Figures 3 and 4) . However, there are important differences to note between the surgeries with respect to change in pressure over time and the bleb morphology and function.
Proper preparation, placement, and priming of a gel stent implant should result in a low-lying and diffuse bleb that is morphologically different than what is typically observed following trabeculectomy ( Figure 5) . Additionally, the internal resistance of the gel stent is designed to prevent acute decompression in the early postoperative period.
Optimal intraocular pressure in the early postoperative period
Postoperative management of patients following gel stent implantation is guided by the philosophy of "start low, stay low" with respect to IOP. Gel Stent Implantation-Recommendations clinical hypotony-related complications compared to similar IOP after trabeculectomy, and such cases after gel stent implantation may be amenable to observation without immediate intervention.
There are several factors that may lead to the development of hypotony following gel stent implantation. For example, impaired aqueous production rates (e.g. in patients with uveitis); wound leak; and eye rubbing. 
Low intraocular pressure (clinically significant hypotony)
In instances where clinically significant hypotony is suspected, the evaluation and management should be differentiated based on the likely or suspected cause, with extra attention given to those cases in which there is accompanying loss of visual acuity. In exceptional situations where Review Glaucoma viscoelastic materials are needed to increase the viscosity of aqueous in patients with symptomatic hypotony, thereby increasing resistance to outflow, high-molecular-weight cohesive viscoelastic should not be used and, instead, low-molecular-weight dispersive viscoelastic should be used to partially fill the AC (Figure 2) . Discretion should be used regarding the volume of viscoelastic used. Alternatively, the use of air, either alone or with viscoelastic, can be considered.
Elevated intraocular pressure
IOP measurements above the target range may not be indicative of implant failure, but care should be taken to find the cause and attempt to fix it if necessary ( Table 1) . Confirming proper implant connection to the AC and subconjunctival space should always be the first step in the evaluation.
After confirming implant connection, other plausible mechanisms for postoperative IOP above the target range include retained viscoelastic, blockade of the implant lumen in the AC, fibrosis, bleb encapsulation, and impaired bleb function, similar to what may be encountered after trabeculectomy and tube surgeries. 25, 26 The ostium of the implant can be blocked by a number of mechanisms, including, but not limited to, iris occlusion, lens fragment material (in the case of combined surgeries), and blood. Several risk factors have been identified to increase the risk of iris occlusion with tube shunts that may apply to implantation of a gel stent, including intraoperative floppy iris syndrome (IFIS), peripheral iris abnormality, low positioning into the angle/iris root (Figure 6 ), narrow angle, phakic lens status, and previous iridotomy in the vicinity of the implantation (owing to the risk of iris strands incarcerating the internal ostium). 27, 28 Iris occlusion of the gel stent implant is a rarely occurring event when proper implant placement is achieved. 14 Instances in which the implant is not visible under the conjunctiva indicate a need for a more aggressive intervention, up to and including surgical revision.
On the other hand, less commonly, 30 when encapsulation occurs, the use of preservative-free aqueous suppressant, including oral acetazolamide if needed, with reevaluation at a later date, is a reasonable first approach ( Figure 7) . In some cases of encapsulation, needling may be considered, although there is a risk of recurrence. It is the authors' opinion that a flat bleb with elevated IOP in the early postoperative period is most likely due to fibrosis, high interstitial resistance, or implant blockage, whereas restriction of flow due to encapsulation of the bleb is a much more likely cause of a dome-shaped or elevated bleb, especially if it occurs 1 month postoperatively. The response to DOC may help determine if the bleb is functional, which, in turn, will dictate the course of additional intervention. Gel Stent Implantation-Recommendations Similarly, the change of IOP at week 1 compared to day 1 (which the authors refer to as Week 1 Delta) may be used as an early prognosticator of bleb function and whether appropriate outflow has been achieved. Based on this, we propose an algorithm based on the week 1 IOP that may be useful for management of cases with "atypical" pressure measurements ( Figure 4 and Table 1 ). It is the authors' collective experience that a significant 
Bleb characteristics and the role of needle revision
Traditional clinical assessment of bleb morphology used for trabeculectomy blebs may not have prognostic value with regard to optimal flow characteristics. Instead, the surgeon should rely more on the IOP rather than solely on the appearance of bleb to guide assessment of bleb function.
Following implantation of a gel stent, the bleb will stabilize over time, with the rate of change influenced by the process of postoperative wound healing. If the desired pressure is achieved and the eye appears quiet with a low diffuse bleb, steroids can be tapered as early as 4-6 weeks after surgery. However, in eyes with active inflammation or when future interventions seem necessary, steroids should be continued. When there is restriction of flow to the bleb, there may be a need for needle revision. As with trabeculectomy, the prognosis for needle revision is better for a flatter bleb compared to cases in which the bleb is elevated, thickened, or has a cystic, dome-shaped appearance, especially if the gel stent is not visible through the bleb.
In cases where bleb needling is performed, adjunctive use of MMC or fluorouracil (5-FU) may be useful. When MMC is used, the authors use a dose that is similar to or slightly higher than what was used intraoperatively during hydroexpansion, typically in concentrations ranging from 0.1 mg/ mL to 0.4 mg/mL in a total volume of 0.1 mL. It is also the authors' experience that while a successful needle revision of a bleb following gel stent implantation will immediately lower tissue resistance (defined by a significant lowering of IOP after needling), the instantaneous blebforming response is typically not as quick as that seen with needling a bleb following trabeculectomy. However, if the target IOP is not achieved, it is unlikely that needling will be successful. In general, an IOP under 10 mmHg after needling is more likely to result in a successful outcome.
Finally, use of a cohesive viscoelastic to enlarge the space around the bleb may facilitate proper bleb/space formation.
There may be a role for DOC in certain cases, either alone or following an attempted needle revision. As a standalone intervention, DOC is most helpful when the bleb is elevated but the pressure is not well controlled (for instance, if the month 1 IOP is ≥17 mmHg and/or the Week 1 Delta is ≥6 mmHg), then instructing the patient to perform DOC at home could help reestablish optimal flow.
Conclusions
The logical, step-wise approach to the management of the pre-, intra-, and postoperative periods in surgeries involving the gel stent implant is intended as guidance to fellow surgeons using this MIGS device; they are meant to complement, and not to replace, formal training with the gel stent.
The Expert Principles for gel stent implantation described herein are organized into three phases: preparation, placement, and priming, with specific steps of each informed by three guiding principles-to minimize bleeding, lower conjunctival resistance, and control inflammation. While these recommendations are intended as guidance to fellow surgeons, the suggested approach may help minimize the impact of factors that could lead to a less desirable outcome.
These guidelines are based on the amalgamation of evidence-based practices and the surgeon-authors' considerable experience with the gel stent implant.
Just as this approach evolved over time and was enhanced by accumulation of more knowledge and experience, it is plausible that surgeons incorporating the gel stent implant into their treatment armamentarium for glaucoma will witness more favorable outcomes as they perform more cases.
